Paul Nathan
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers 39
- Cutaneous Melanoma Detection and Management 29
- CAR-T cell therapy research 26
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 31
- Ophthalmology top 1%
- Ocular Oncology and Treatments 27
-
- Renal cell carcinoma treatment 61
- Immunology top 2%
- Immunotherapy and Immune Responses 31
-
- Melanoma and MAPK Pathways 50
- Co-authors
- Dirk SchadendorfCaroline RobertJames LarkinKeith T. FlahertyBruce G. MacMillanVicky GohReinhard DummerJaspal Juttla
- Cited by
- OncologyCancer ResearchOphthalmology
- Journals
- Journal of Clinical Oncology (67 papers)Annals of Oncology (24 papers)European Journal of Cancer (9 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Paul Nathan
266 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 3.8k
- Cancer Research 1.0k
- Ophthalmology 573
- Pulmonary and Respiratory Medicine 2.0k
- Immunology 1.1k
Countries citing papers authored by Paul Nathan
This map shows the geographic impact of Paul Nathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Nathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Nathan more than expected).
Fields of papers citing papers by Paul Nathan
This network shows the impact of papers produced by Paul Nathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Nathan. The network helps show where Paul Nathan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Paul Nathan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 8 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 32 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 19 | |
| 8 | 2021 | 2 | |
| 9 | 2020 | 52 | |
| 10 | 2019 | 19 | |
| 11 | 2019 | 4 | |
| 12 | 2019 | 16 | |
| 13 | 2018 | 9 | |
| 14 | Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma | 2017 | 5 |
| 15 | 2016 | 19 | |
| 16 | 2015 | 38 | |
| 17 | 2011 | 84 | |
| 18 | 2010 | 9 | |
| 19 | 2009 | 64 | |
| 20 | 2009 | 6 |
About Paul Nathan
Paul Nathan is a scholar working on Oncology, Ophthalmology, Rehabilitation, Cancer Research and Transplantation, having authored 272 papers that have together received 7.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (61 papers), Melanoma and MAPK Pathways (50 papers), Cancer Immunotherapy and Biomarkers (39 papers), Cancer Genomics and Diagnostics (31 papers), Immunotherapy and Immune Responses (31 papers), Cutaneous Melanoma Detection and Management (29 papers), Ocular Oncology and Treatments (27 papers) and CAR-T cell therapy research (26 papers). The work is most often cited by research in Oncology (3.8k citations), Cancer Research (1.0k citations), Ophthalmology (573 citations), Pulmonary and Respiratory Medicine (2.0k citations) and Immunology (1.1k citations). Paul Nathan has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Dirk Schadendorf, Caroline Robert, James Larkin, Keith T. Flaherty, Bruce G. MacMillan, Vicky Goh, Reinhard Dummer, Jaspal Juttla, Anup Vinayan and Claus Garbe. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, The Lancet Oncology and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.